<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Prospective data directly investigating the role of endogenous sex hormones in <z:mp ids='MP_0002055'>diabetes</z:mp> risk have been scant, particularly in women </plain></SENT>
<SENT sid="1" pm="."><plain>We aimed to examine comprehensively plasma sex hormones in connection with risk of developing type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in postmenopausal women </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We conducted a prospective, nested case-control study of plasma <z:chebi fb="0" ids="23965">oestradiol</z:chebi>, <z:chebi fb="51" ids="17347">testosterone</z:chebi> and dehydroepiandrosterone <z:chebi fb="0" ids="16189">sulfate</z:chebi> and risk of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in a cohort of women health professionals with a mean age of 60.3 and 12.2 years since menopause </plain></SENT>
<SENT sid="3" pm="."><plain>Among women not using hormone therapy and free of baseline <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e>, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and <z:mp ids='MP_0002055'>diabetes</z:mp>, 359 incident cases of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> were matched with 359 controls during an average follow-up of 10 years </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:chebi fb="0" ids="23965">Oestradiol</z:chebi> and <z:chebi fb="51" ids="17347">testosterone</z:chebi> were each strongly and positively associated with risk of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>After adjustment for BMI, family history, lifestyle and reproductive variables, the multivariable relative risks (95% CI) comparing the highest vs lowest quintile were 12.6 (2.83-56.3) for total <z:chebi fb="0" ids="23965">oestradiol</z:chebi> (p = 0.002 for trend), 13.1 (4.18-40.8) for free <z:chebi fb="0" ids="23965">oestradiol</z:chebi> (p &lt; 0.001 for trend), 4.15 (1.21-14.2) for total <z:chebi fb="51" ids="17347">testosterone</z:chebi> (p = 0.019 for trend) and 14.8 (4.44-49.2) for free <z:chebi fb="51" ids="17347">testosterone</z:chebi> (p &lt; 0.001 for trend) </plain></SENT>
<SENT sid="6" pm="."><plain>These associations remained robust after adjusting and accounting for other <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> components and baseline HbA(1c) levels </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS/INTERPRETATION: In postmenopausal women, higher plasma levels of <z:chebi fb="0" ids="23965">oestradiol</z:chebi> and <z:chebi fb="51" ids="17347">testosterone</z:chebi> were strongly and prospectively related to increased risk of developing type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>These prospective data indicate that endogenous levels of sex hormones may play important roles in the pathogenesis of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>ClinicalTrials.gov ID no.: NCT00000479 </plain></SENT>
</text></document>